Two-Year Follow-Up of a Patient With Successful Continuation of Clozapine Treatment Despite Morning Pseudoneutropenia
J Clin Psychiatry 2004;65(9):1281[letter]
© Copyright 2015 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
Sir: Agranulocytosis occurs in 1% to 2% of patients treated with clozapine. Thus, if neutropenia (absolute neutrophil count [ANC] of < 1500/µL) occurs during clozapine treatment, physicians generally interrupt the drug treatment and do not reintroduce it. Lithium and granulocyte colony-stimulating factor may be used to reverse clozapine-induced granulocytopenia.1 We have previously reported the case of a patient who was able to continue clozapine treatment despite developing “morning pseudoneutropenia” (MPN).2